ABERA — Abera Bioscience AB Share Price
Last trade - 00:00- SEK74.92m
- SEK71.60m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 13.25 | ||
| Price to Tang. Book | 19.88 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -297.05% | ||
| Return on Equity | -149.05% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | SEKm | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Abera Bioscience AB is a Sweden-based company, which is active in biotechnology. Abera Bioscience is platform and vaccine development company active in the medical, molecular and microbiological field. The Company’s purpose is to develop vaccine candidates based on its vaccine delivery platform to late pre-clinical or early clinical phase and to find licensing partners for further development of the vaccines. The technology is mainly used in the development of new vaccines where the focus is on the main areas of pneumococci and immunooncology. The business is located around the Nordic market.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- November 3rd, 2012
- Public Since
- February 24th, 2021
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- AktieTorget Stock Exchange
- Shares in Issue
- 14,463,462
- Address
- Dragarbrunnsgatan 45, Box 1747, UPPSALA, 751 47
- Web
- https://aberabio.com/
- Phone
- Auditors
- PWC Sweden
Similar to ABERA
Aptahem AB
AktieTorget Stock Exchange
Arcede Pharma AB
AktieTorget Stock Exchange
Carbiotix AB (publ)
AktieTorget Stock Exchange
Chosa Oncology AB
AktieTorget Stock Exchange
Curasight A/S
AktieTorget Stock Exchange
FAQ
As of Today at 19:00 UTC, shares in Abera Bioscience AB are trading at SEK5.18. This share price information is delayed by 15 minutes.
Shares in Abera Bioscience AB last closed at SEK5.18 and the price had moved by +7.69% over the past 365 days. In terms of relative price strength the Abera Bioscience AB share price has underperformed the FTSE Global All Cap Index by -0.66% over the past year.
There is no consensus recommendation for this security.
Abera Bioscience AB does not currently pay a dividend.
Abera Bioscience AB does not currently pay a dividend.
Abera Bioscience AB does not currently pay a dividend.
To buy shares in Abera Bioscience AB you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of SEK5.18, shares in Abera Bioscience AB had a market capitalisation of SEK74.92m.
Here are the trading details for Abera Bioscience AB:
- Country of listing: Sweden
- Exchange: AKT
- Ticker Symbol: ABERA
Based on an overall assessment of its quality, value and momentum Abera Bioscience AB is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Abera Bioscience AB. Over the past six months, its share price has outperformed the FTSE Global All Cap Index by +0.59%.
As of the last closing price of SEK5.18, shares in Abera Bioscience AB were trading +10.12% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Abera Bioscience AB PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at SEK5.18.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Abera Bioscience AB's directors